PROMETHEUS®
Therapeutics & Diagnostics
For the person in every patient

PROMETHEUS® Anser® ADA
Cat. # 3170

Product Description

Serum concentrations of adalimumab (ADA) may vary among equally dosed patients which can ultimately affect patient outcomes. Suboptimal levels of ADA have been linked to lower response rates in IBD patients. Furthermore, some patients may develop immunogenicity to ADA by producing antibodies to adalimumab (ATA). The presence of ATA has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of ADA and ATA levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient's loss of response.

The PROMETHEUS Anser ADA test is a next generation quantitative monitoring assay that allows healthcare providers to measure and monitor serum ADA and ATA levels at anytime during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient's loss of response and help patient management by providing information to help decide an appropriate course of action.

- A quantitative monitoring analysis of ADA and ATA levels.
- PROMETHEUS Anser ADA is only offered at Prometheus.
- **Specimen Requirements** - Serum, 2.0 ml: SST or Red Top Tube.
- **Shipping and Handling** - Ambient or refrigerated.
- **Storage Conditions/Stability** -7 days Ambient or 9 days Refrigerated
- **Turn Around Time** - 3 business days from date of receipt.
- **Reference Range:**
    - Serum adalimumab (ADA) concentration: <1.6 ug/mL
    - Antibody to adalimumab (ATA) concentration: <1.7 U/mL

Facilities Description

- Prometheus is located in San Diego, CA. Tax ID# 33-0685754 NPI# 1073642641.
- Licensed in several states including New York and California.
- Prometheus Laboratories Inc. is CLIA certified and accredited by the College of American Pathologists. This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test may be covered by one or more US pending or issued patents - see prometheuslabs.com for details.

CPT Codes

84999 (x1), Unlisted Chemistry Procedure (Quantitative assay that simultaneously measures serum adalimumab (ADA) and antibodies to adalimumab (ATA) concentrations).

Literature References

- Karmiris K., et al., Influence of Trough Serum Levels and Immunogenicity on Long-Term Outcome of Adalimumab Therapy in Crohn's Disease.Gastroenterology 2009;137:1628-1640.

- Wang S., et al., Influence of Trough Serum Drug Level and Immunogenicity on the Lack of Response to Adalimumab Therapy in IBD Patients. Am J Gastro 2012;107 (supplement 1): Abstract 1680.